In summary, this cohort study provided evidence supporting the association of tirzepatide treatment, compared to GLP-1 RAs, with lower hazards of all-cause mortality and adverse cardiovascular or kidney events through a head-to-head comparison in patients with type 2 diabetes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.